Australia seems poised to gain access to potentially transformative treatment for obesity: Retatrutide. The dual agonist – acting on both GLP-1 and GIP receptors – shows promising outcomes in international studies, https://retatrutide-australia-tr261548.sharebyblog.com/41612437/the-new-retatrutide-australia-the-prospect-for-weight-loss